Welcome to our dedicated page for Reliance Global Group news (Ticker: EZRA), a resource for investors and traders seeking the latest updates and insights on Reliance Global Group stock.
Reliance Global Group reports news about its insurance and InsurTech operating foundation, financial results and strategic venture investments. Recurring company updates cover the RELI Exchange platform for independent insurance agencies, agency recruiting and productivity initiatives, and business updates tied to the company's insurance commission-based operations.
News also covers EZRA International Group and Reliance's ownership-driven investments in technology and life sciences. Recent themes include Enquantum's post-quantum cryptography platform, LifeSci Global's healthcare investment mandate, Innervate Radiopharmaceuticals' radiopharmaceutical development work, conference participation and governance or capital-allocation updates tied to the company's strategic ventures model.
Reliance Global Group (Nasdaq: EZRA) promoted Moshe Fishman to Senior Vice President, Strategic Ventures to lead its EZRA Group International platform while continuing to support the core insurance business.
Fishman will source and execute majority or controlling acquisitions, scale post-close integration, and advance recent transactions including announced majority stakes in Scentech Medical and Enquantum Ltd.
Reliance Global Group (Nasdaq: EZRA) entered a non-binding term sheet on Jan 26, 2026 to acquire a controlling stake in Enquantum, a post-quantum cryptography hardware company. Reliance advanced funding via a secured promissory note on Jan 15, 2026 that is secured by all Enquantum assets and payable within 60 days if no definitive agreement is reached, with amounts applied to early payment milestones if a deal closes. Enquantum holds a 2025 patent for FPGA-based quantum-resistant encrypted communications and is developing NIST-compliant, hardware-accelerated PQC targeting terabit Ethernet speeds. The transaction remains conditional on due diligence and definitive agreements.